北京：推动商保公司与医药企业开展协商定价，加速商保创新药目录落地实施

Group 1 - The core viewpoint of the news is the introduction of measures to support the high-quality development of commercial health insurance in Beijing, focusing on collaboration with the pharmaceutical industry [1][2] Group 2 - The measures propose the establishment of a collaborative development platform to enhance communication between commercial insurance companies and innovative pharmaceutical enterprises, facilitating information sharing and demand matching for innovative drugs and medical devices [1] - There is an emphasis on encouraging commercial insurance companies to include reasonably priced innovative drugs and high-value medical devices related to cancer, gene therapy, and rare diseases in their coverage [1] - The measures advocate for the innovation of payment models for innovative drugs, including exploring multi-modal payment options such as payment by efficacy and installment payments [1][2] Group 3 - The measures support the clinical application of innovative drugs by allowing them to be fast-tracked for listing without affecting the basic medical insurance self-payment rate [2] - Innovative drugs are exempt from certain restrictions and can be supplied through a "dual-channel" mechanism in designated medical institutions or contracted pharmacies [2] - Costs for eligible new drugs and technologies will not be included in the DRG payment standards and will be paid separately after review [2] Group 4 - The measures encourage an increase in investment in innovative drugs and medical devices, promoting financial support for the innovative pharmaceutical industry through various market-based investment methods [1]